Laryngeal Cancer: Navigating Trials and Patient Eligibility

The diagnostic odyssey

Laryngeal cancer is a significant health concern, often presenting a complex diagnostic journey for patients. Symptoms such as hoarseness, throat pain, and difficulty swallowing can lead to a variety of misdiagnoses. The multifaceted nature of laryngeal cancer, combined with its relatively low incidence compared to other cancers, makes it challenging to identify eligible patients for clinical trials. Additionally, the stigma associated with head and neck cancers can deter patients from seeking timely medical attention, further complicating the diagnostic process. As a result, many individuals may experience delays in receiving appropriate care and treatment, which can adversely affect their prognosis.

The trial landscape right now

Currently, our live trial registry indicates that there are three recruiting trials for laryngeal cancer across three sites in two countries: the United States and France. The leading sponsors include the Massachusetts Eye and Ear Infirmary, which is responsible for two trials, and the Center Eugene Marquis, which sponsors one trial. Notably, the trials include:

• NCT05150093 — "Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor" (sponsor: Massachusetts Eye and Ear Infirmary; United States)
• NCT05150106 — "Characterization of Clinical Phenotypes of Laryngeal Dystonia and Voice Tremor" (sponsor: Massachusetts Eye and Ear Infirmary; United States)
• NCT06627075 — "Optical Surface Guidance for External Radiotherapy of Head and Neck Cancer" (sponsor: Center Eugene Marquis; France)

These trials are crucial for advancing our understanding of laryngeal cancer and improving treatment options, yet the challenge remains to effectively identify and enroll eligible patients.

How we detect the match

Leveraging an HL7/FHIR + AI integration layer presents a transformative approach to patient matching for clinical trials. By utilizing specific FHIR resources such as Condition, Observation, MedicationRequest, and DiagnosticReport, healthcare systems can automate the identification of eligible patients without the need for manual chart reviews. For example, conditions related to laryngeal cancer can be matched against existing patient records, while observations may include relevant symptoms or diagnostic findings. Additionally, lab results and genetic data can further refine eligibility criteria based on computable phenotypes. This streamlined process not only enhances the efficiency of patient recruitment but also ensures that patients who may benefit from participation in trials are not overlooked.

Beyond the trial: better care

The integration of HL7/FHIR and AI does not solely serve the purpose of matching patients to clinical trials; it also plays a pivotal role in improving overall patient care. By reducing the diagnostic odyssey, healthcare providers can facilitate quicker and more accurate diagnoses, leading to timely interventions. Enhanced coordination among healthcare teams ensures that patients receive comprehensive monitoring and support, whether or not they choose to enroll in a trial. This holistic approach contributes to better patient outcomes and a more efficient healthcare system, ultimately benefiting all stakeholders involved.

The takeaway

Laryngeal cancer poses unique challenges in patient diagnosis and trial recruitment. However, with innovative approaches that leverage technology and real-time trial intelligence, we can improve patient matching, streamline the diagnostic process, and enhance overall care for those affected by this disease.